Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Immunogen Inc (IMGN)
Immunogen Inc (IMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,806,861
  • Shares Outstanding, K 266,264
  • Annual Sales, $ 108,780 K
  • Annual Income, $ -222,930 K
  • 60-Month Beta 1.22
  • Price/Sales 71.77
  • Price/Cash Flow N/A
  • Price/Book 13.90
Trade IMGN with:

Options Overview Details

View History
  • Implied Volatility 8.77% ( -1.86%)
  • Historical Volatility 185.93%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 290.07% on 02/27/23
  • IV Low 8.77% on 12/04/23
  • Put/Call Vol Ratio 0.40
  • Today's Volume 2,214
  • Volume Avg (30-Day) 11,867
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 180,742
  • Open Int (30-Day) 120,620

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.12
  • Number of Estimates 11
  • High Estimate 0.22
  • Low Estimate 0.07
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +152.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.26 +104.38%
on 11/13/23
29.44 -1.04%
on 11/30/23
+12.84 (+78.85%)
since 11/03/23
3-Month
12.43 +134.39%
on 10/23/23
29.44 -1.04%
on 11/30/23
+13.22 (+83.01%)
since 09/01/23
52-Week
3.61 +708.18%
on 03/23/23
29.44 -1.04%
on 11/30/23
+23.67 (+432.63%)
since 12/02/22

Most Recent Stories

More News
Why Abbvie Stock Popped Today

The company announces a major deal worth over $10 billion.

ABBV : 144.45 (+0.73%)
IMGN : 29.15 (-0.58%)
Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio

AbbVie is spending more than $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales

$SPX : 4,564.07 (-0.67%)
$DOWI : 36,186.05 (-0.16%)
$IUXX : 15,802.39 (-1.22%)
IMGN : 29.15 (-0.58%)
ABBV : 144.45 (+0.73%)
ImmunoGen: Q3 Earnings Snapshot

ImmunoGen: Q3 Earnings Snapshot

IMGN : 29.15 (-0.58%)
Pioneering the Path to Cure Cancer: 2023's Biotech Innovations

VANCOUVER – Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their “Cancer Moonshot” initiative, an ambitious plan to slash cancer rates in half within...

RY : 91.21 (+0.13%)
RY.TO : 123.31 (+0.30%)
ONCY : 1.4020 (-1.27%)
ONC.TO : 1.91 (+0.53%)
LLY : 584.52 (+0.08%)
IMGN : 29.15 (-0.58%)
AZN : 64.98 (+0.29%)
MRK : 104.97 (+1.46%)
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

/PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their "Cancer Moonshot"...

ONC.TO : 1.91 (+0.53%)
ONCY : 1.4020 (-1.27%)
IMGN : 29.15 (-0.58%)
MRK : 104.97 (+1.46%)
AZN : 64.98 (+0.29%)
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 20, 2023 – USA News Group  –  Earlier this year, the US White House requested over $2.8 billion in funding from...

LLY : 584.52 (+0.08%)
RY : 91.21 (+0.13%)
RY.TO : 123.31 (+0.30%)
ONCY : 1.4020 (-1.27%)
ONC.TO : 1.91 (+0.53%)
IMGN : 29.15 (-0.58%)
AZN : 64.98 (+0.29%)
MRK : 104.97 (+1.46%)
Markets Today: Stocks Push Higher on Strength in China and Europe

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are up +0.17%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are up +0.18% at a 1-week high. Stock indexes this morning are moderately...

ESZ23 : 4,570.50 (-0.66%)
NQZ23 : 15,829.00 (-1.22%)
COP : 114.75 (-0.42%)
DVN : 44.76 (-0.91%)
FANG : 153.84 (-0.28%)
XOM : 102.68 (-0.30%)
MRO : 25.13 (-1.22%)
SLB : 52.12 (-0.52%)
VLO : 126.60 (+0.17%)
MET : 64.44 (+1.07%)
PLTR : 18.31 (-9.67%)
ADBE : 602.53 (-1.62%)
ImmunoGen: Q2 Earnings Snapshot

ImmunoGen: Q2 Earnings Snapshot

IMGN : 29.15 (-0.58%)
ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates

/PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel...

IMGN : 29.15 (-0.58%)
MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results.

MLTX : 46.58 (+1.04%)
IMGN : 29.15 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla...

See More

Key Turning Points

3rd Resistance Point 29.88
2nd Resistance Point 29.61
1st Resistance Point 29.47
Last Price 29.15
1st Support Level 29.06
2nd Support Level 28.79
3rd Support Level 28.65

See More

52-Week High 29.44
Last Price 29.15
Fibonacci 61.8% 19.57
Fibonacci 50% 16.52
Fibonacci 38.2% 13.47
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar